Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review.
Sohaib Sanan RoomiWaqas UllahFaizan AhmedSoban FarooqUsama SadiqAsad ChohanMunnam JafarMaryum SaddiqueShristi KhanalRobert WatsonMargot BoigonPublished in: Journal of medical Internet research (2020)
In this cohort of patients with COVID-19, neither HCQ nor TCZ offered a significant reduction in in-hospital mortality, upgrade to intensive medical care, invasive mechanical ventilation, or acute renal failure needing dialysis. These results are similar to the recently published preliminary results of the HCQ arm of the Recovery trial, which showed no clinical benefit from the use of HCQ in hospitalized patients with COVID-19 (the TCZ arm is ongoing). Double-blinded randomized controlled trials are needed to further evaluate the impact of these drugs in larger patient samples so that data-driven guidelines can be deduced to combat this global pandemic.
Keyphrases
- mechanical ventilation
- respiratory failure
- acute respiratory distress syndrome
- intensive care unit
- randomized controlled trial
- sars cov
- coronavirus disease
- liver failure
- rheumatoid arthritis
- study protocol
- chronic kidney disease
- drug induced
- extracorporeal membrane oxygenation
- case report
- meta analyses
- phase iii
- clinical trial
- end stage renal disease
- cross sectional
- juvenile idiopathic arthritis
- phase ii
- systematic review
- hepatitis b virus